Janux Therapeutics, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023; filed November 7, 2023. Janux is a clinical-stage biopharmaceutical company developing tumor-activated cancer immunotherapies. It has no product sales; reported revenue is from its Merck collaboration.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Collaboration revenue | $2.5m | $1.8m | $5.6m | $5.8m |
| Research and development | $11.9m | $13.7m | $42.7m | $38.0m |
| General and administrative | $6.4m | $6.1m | $19.8m | $16.6m |
| Operating loss | $15.8m | $18.0m | $56.8m | $48.8m |
| Interest income | $4.2m | $1.3m | $10.3m | $1.8m |
| Net loss | $11.6m | $16.7m | $46.5m | $47.0m |
| Basic and diluted loss per share | $0.25 | $0.40 | $1.08 | $1.13 |
Gross margin is not a meaningful disclosed measure for this development-stage business; the filing reports collaboration revenue and operating expenses, not product sales or cost of product revenue.
- Cash and liquidity: At September 30, 2023, cash and cash equivalents were $17.2m and short-term investments were $332.6m. Including $0.8m restricted cash, total cash, cash equivalents and short-term investments were about $350.5m; $0.8m was unavailable for current use. Current assets were $355.2m and current liabilities $14.5m.
- Cash flow: Nine-month operating cash use was $40.7m, versus $31.0m in 2022. Investing used $52.3m, largely reflecting net purchases of short-term investments; financing provided $58.7m, including $56.5m net proceeds from the July offering. Cash, cash equivalents and restricted cash ended at $18.0m.
- Debt and obligations: The filing reports no borrowing debt. Operating lease liabilities totaled $24.9m, including $1.5m current; the lease has a 9.3-year remaining term. Accumulated deficit was $157.0m.
Changes versus comparable periods
- Q3 net loss narrowed by $5.1m year over year, mainly as higher interest income and lower R&D expense more than offset higher G&A. R&D declined $1.8m, including lower preclinical/unallocated costs; JANX007 direct costs increased.
- For the first nine months, net loss was nearly flat, improving $0.5m, even though operating loss widened $8.0m. Interest income rose $8.5m, primarily due to higher interest rates, substantially offsetting higher operating costs.
- Nine-month R&D increased $4.7m, driven mainly by higher personnel, facilities and other indirect costs and JANX007 spending; JANX008 direct costs fell $2.6m. G&A increased $3.2m, primarily from compensation and personnel/facilities costs.
- Cash and cash equivalents declined from $51.4m at December 31, 2022 to $17.2m, while short-term investments increased from $275.6m to $332.6m. The July 2023 underwritten offering raised $56.5m net and included common shares and pre-funded warrants. Common shares outstanding increased from 41.6m at year-end to 46.2m at September 30.
Outlook, programs and risks
- Management expects substantial operating losses for the next several years and says current cash, cash equivalents and short-term investments should fund planned operations and capital requirements for at least 12 months after the report and through 2027. This is a forward-looking estimate based on assumptions; Janux says additional capital will be needed to complete development and commercialization.
- JANX007, a PSMA-targeted TRACTr, is in a Phase 1 trial for metastatic castration-resistant prostate cancer. The company reported interim data in July 2023, including meaningful PSA declines, and characterized the safety and pharmacokinetic profile as differentiated; these are preliminary company-reported results. JANX008, an EGFR-targeted TRACTr, is in Phase 1 for several solid tumors, with its first patient dosed in April 2023. The company anticipated clinical-program updates in 2024.
- The TROP2-TRACTr development candidate has been identified. JANX009, a PD-L1-TRACIr, completed IND-enabling studies and manufacturing. The company said it was assessing preclinical pipeline priorities.
- Under the Merck agreement, Merck selected two collaboration targets. Janux is eligible for development/regulatory milestones of up to $142.5m per target, commercial milestones of up to $350m per licensed product, and tiered royalties. These amounts are contingent, not assured. Merck may terminate the agreement at its discretion. All Janux revenue to date was attributable to this single customer; $3.6m of deferred revenue remained at quarter-end, and remaining research obligations were estimated at 0.9 years for the second target.
- Key risks include clinical safety and efficacy uncertainty, including cytokine release syndrome and healthy-tissue toxicity risks associated with T-cell engagers; trial enrollment, regulatory and manufacturing delays; reliance on third parties; dependence on Merck for collaboration revenue; financing and potential shareholder dilution; and interest-rate, banking-system, inflation and broader market uncertainties. The filing reports no material legal proceedings and no material disruption to operations from the cited macroeconomic risks to date.
- The July equity offering generated dilution. A separate $150m at-the-market program was available at quarter-end, with no activity reported under that agreement during the first nine months of 2023. Management reported effective disclosure controls and no material quarterly change in internal control over financial reporting.
Most important facts for investors to verify
- Whether subsequent JANX007 and JANX008 trial data support the preliminary observations, including efficacy, CRS and other safety findings, and whether timelines or trial plans change.
- Whether the stated cash runway through 2027 remains supportable as clinical spending grows, and how much financing may be required and on what terms.
- Merck research progress, continuation of the collaboration, and the timing and conditions for any milestone or royalty payments.
- Future operating cash burn, interest income sensitivity, and the liquidity, maturity and valuation profile of the short-term investment portfolio.
- Potential dilution from outstanding options, pre-funded warrants, equity-plan reserves and any use of the remaining ATM capacity.